Montral Syrup and Montral tablets (Montelukast + Levocetirizine)

• Composition :
  Montelukast 4mg+ Levocetirizine 2.5mg/5ml.
• Indications :
  For the treatment of allergic rhinitis
• Pharmacodynamics :
  Montelukast inhibits physiologic actions of LTD4 at the CysLT1 receptors which play a main role in pathophysiology of allergic rhinitis. Levocetirizine, the R-enantiomer of cetirizine, is a potent and selective antagonist of peripheral H1-receptors.
• Dosage and administration :
  Montral KID Tablets: Children (2-5 years): 1 tablet once daily. Montral Syrup: Children (2-5 years), 5 ml syrup as measured from the given cup, administered once daily. Safety and effectiveness in pediatric patients younger than 2 years of age with seasonal allergic rhinitis have not been established.
• Contraindications :
  Contraindicated in patients with known hypersensitivity to montelukast sodium, levocetirizine or cetirizine or to any other component of this product and in patients with severe renal impairment at less than 10ml/min creatinine clearance.
• Precautions and warnings :
  Patients on therapy with Montelukast may present with systemic eosinophilia, sometimes presenting with clinical features of vasculitis. Neuropsychiatric events have been reported with montelukast. Patients should be monitored closely for the same.
• Drug interactions :
  Montelukast may be administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma. Phenobarbital reduces the plasma concentration of montelukast, which does not necessitate dosage adjustment.
• Adverse reactions :
  Common side effects include dyspepsia, abdominal pain, rash, dizziness, headache, fatigue and fever.
• Therapy Area :
  Anti-Allergics